進藤 岳郎

Last Update: 2019/06/17 21:28:14

Print

Name(Kanji/Kana/Abecedarium Latinum)
進藤 岳郎/シンドウ タケロウ/Shindo, Takero
Primary Affiliation(Org1/Job title)
Kyoto University Hospital/Assistant Professor
E-mail Address
E-mail address
takeros @ kuhp.kyoto-u.ac.jp
Academic Organizations You are Affiliated to in Japan
Organization name(Japanese) Organization name(English)
日本内科学会 The Japanese Society of Internal Medicine
日本血液学会 The Japanese Society of Hematology
日本造血細胞移植学会 The Japanese Society of Hematopoietic Cell Transplantation
日本HTLV-1学会 The Japanese Society of HTLV-1 and associated diseases
日本組織適合性学会 The Japanese Society for Histocompatibility and Immunogenetics
日本臨床検査医学会 The Japanese Society of Laboratory Medicine
血液疾患免疫療法学会 The Japanese Society of Immunotherapy for Hematological Disorders
日本臨床免疫学会 The Japanese Society of Clinical Immunology
Academic Degree
Field(Japanese) Field(English) University(Japanese) University(English) Method
博士(医学) 京都大学
Work Experience
Period Organization(Japanese) Organization(English) Job title(Japanese) Job title(English)
1997/05/01-1998/05/31 京都大学医学部附属病院 医員(研修医) Resident
1998/06/01-2000/05/31 神鋼病院 医員(研修医) Resident
2000/06/01-2002/03/31 市立長浜病院 医員 Clinical Fellow
2007/04/01-2008/12/31 関西電力病院 医員 Clinical Fellow
2009/02/01-2010/06/30 フレッドハッチンソン癌研究センター Fred Hutchinson Cancer Research Center 博士研究員 Post-doctoral research fellow
2010/07/01-2012/06/30 マイアミ大学シルベスター癌センター University of Miami Sylvester Comprehensive Cancer Center 博士研究員 Post-doctoral research fellow
2012/08/01-2016/10/31 佐賀大学医学部血液・呼吸器・腫瘍内科 助教 Assistant Professor
2016/11/01- 京都大学医学部附属病院 助教 Assistant Professor
Personal Profile
(Japanese)
血液内科全般の診療活動に携わりつつ、造血幹細胞移植を含めた各種治療法の最適化を目指している。専門とするのは免疫学で、移植医療やがん医療全般への応用を試みている。またHTLV-1や血液疾患全般の啓発活動にも力を入れている。
(English)
I am involved in clinical activity of hematology, and am also trying to improve several therapeutic modalities including hematopoietic stem cell transplantation. Through immunological approaches, I am trying to apply novel methodologies in transplant and oncology areas. In addition, I also conduct enlightenment activity in HTLV-1 and other hematologic diseases.
Language of Instruction
Language
English
Japanese
ORCID ID
https://orcid.org/0000-0002-2085-6151
researchmap URL
https://researchmap.jp/7000018457
Research Topics
(Japanese)
移植免疫学、腫瘍免疫学
(English)
Transplant immunology, Tumor immunology
Overview of the research
(Japanese)
同種造血幹細胞移植におけるGVHDとGVTの最適化
(English)
Manipulating GVHD and GVT in allogeneic hematopoietic stem cell transplantation
Published Papers
Author Author(Japanese) Author(English) Title Title(Japanese) Title(English) Bibliography Bibliography(Japanese) Bibliography(English) Publication date Refereed paper Language Publishing type Disclose
Kamachi K, Shindo T*, Miyahara M, Kitaura K, Akashi M, Shin-I T, Suzuki R, Ohshima K, Kimura S. Kamachi K, Shindo T*, Miyahara M, Kitaura K, Akashi M, Shin-I T, Suzuki R, Ohshima K, Kimura S. Kamachi K, Shindo T*, Miyahara M, Kitaura K, Akashi M, Shin-I T, Suzuki R, Ohshima K, Kimura S. Epstein-Barr virus-related diffuse large B cell lymphoma in mogamulizumab-treated adult T cell leukemia with incomplete T cell reconstitution. Epstein-Barr virus-related diffuse large B cell lymphoma in mogamulizumab-treated adult T cell leukemia with incomplete T cell reconstitution. Epstein-Barr virus-related diffuse large B cell lymphoma in mogamulizumab-treated adult T cell leukemia with incomplete T cell reconstitution. Int J Hematol, 109, 2, 221-227 Int J Hematol, 109, 2, 221-227 Int J Hematol, 109, 2, 221-227 2019/02 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Ureshino H, Kusaba K, Kidoguchi K, Sano H, Nishioka A, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Kimura S. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/kymphoma. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/kymphoma. Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/kymphoma. Ann Hematol, 98, 2, 465-471 Ann Hematol, 98, 2, 465-471 Ann Hematol, 98, 2, 465-471 2019/02 Refereed English Research paper(scientific journal) Disclose to all
Takahagi A, Shindo T, Chen-Yoshikawa TF, Yoshizawa A, Gochi F, Miyamoto E, Saito M, Tanaka S, Motoyama H, Aoyama A, Takaori-Kondo A, Date H. 高萩亮宏、進藤岳郎、陳豊史、吉澤明彦、合地史明、宮本英、斎藤正男、田中里奈、本山英樹、青山明宏、髙折晃史、伊達洋至 Takahagi A, Shindo T, Chen-Yoshikawa TF, Yoshizawa A, Gochi F, Miyamoto E, Saito M, Tanaka S, Motoyama H, Aoyama A, Takaori-Kondo A, Date H. Trametinib attenuates delayed rejection and preserves thymic function in rat lung transplantation. Trametinib attenuates delayed rejection and preserves thymic function in rat lung transplantation. Trametinib attenuates delayed rejection and preserves thymic function in rat lung transplantation. Am J Respir Cell Mol Biol Am J Respir Cell Mol Biol Am J Respir Cell Mol Biol 2019 Refereed English Research paper(scientific journal) Disclose to all
Shindo T, Ureshino H, Kojima H, Tanaka H, Kimura S. 進藤岳郎、嬉野博志、小島裕人、田中秀則、木村晋也 Shindo T, Ureshino H, Kojima H, Tanaka H, Kimura S. Allelic polymorphism of KIRs in chronic myeloid leukemia 慢性骨髄性白血病におけるKIRアレル多型の臨床的意義 Allelic polymorphism of KIRs in chronic myeloid leukemia MHC, 25, 3, 187-195 MHC, 25, 3, 187-195 MHC, 25, 3, 187-195 2018/12 Refereed Japanese Research paper(scientific journal) Disclose to all
Fukushima N, Tomiyasu S, Uji Y, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Ichinohe T, Kimura S. Fukushima N, Tomiyasu S, Uji Y, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Ichinohe T, Kimura S. Fukushima N, Tomiyasu S, Uji Y, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Sueoka E, Ichinohe T, Kimura S. Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase of hematopoietic cell transplantation. Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase of hematopoietic cell transplantation. Monitoring of citrulline and diamine oxidase levels as biomarkers for intestinal mucositis during early-phase of hematopoietic cell transplantation. Blood Cell Ther Blood Cell Ther Blood Cell Ther 2018/08 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Shindo T*, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, Saji H, Kawaguchi A, Kimura S. Ureshino H, Shindo T*, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, Saji H, Kawaguchi A, Kimura S. Ureshino H, Shindo T*, Kojima H, Kusunoki Y, Miyazaki Y, Tanaka H, Saji H, Kawaguchi A, Kimura S. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Allelic polymorphisms of KIRs and HLAs predict favorable responses to tyrosine kinase inhibitors in CML. Cancer Immunol Res, 6, 6, 745-755 Cancer Immunol Res, 6, 6, 745-755 Cancer Immunol Res, 6, 6, 745-755 2018/06 Refereed English Research paper(scientific journal) Disclose to all
Kitamura H, Kubota Y, Yamaguchi K, Kamachi K, Nishioka A, Yokoo M, Shindo T, Ando T, Kojima K, Kimura S. Kitamura H, Kubota Y, Yamaguchi K, Kamachi K, Nishioka A, Yokoo M, Shindo T, Ando T, Kojima K, Kimura S. Kitamura H, Kubota Y, Yamaguchi K, Kamachi K, Nishioka A, Yokoo M, Shindo T, Ando T, Kojima K, Kimura S. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low Multiple Solitary Plasmacytomas Harboring a 17p Deletion. Intern Med, 57, 6, 855-860 Intern Med, 57, 6, 855-860 Intern Med, 57, 6, 855-860 2018/06 Refereed English Research paper(scientific journal) Disclose to all
Fuji S, Utsunomiya A, Inoue Y, Miyagi T, Owatari S, Sawayama Y, Moriuchi Y, Choi I, Shindo T, Yoshida S, Yamasaki S, Yamaguchi T, Fukuda T. Fuji S, Utsunomiya A, Inoue Y, Miyagi T, Owatari S, Sawayama Y, Moriuchi Y, Choi I, Shindo T, Yoshida S, Yamasaki S, Yamaguchi T, Fukuda T. Fuji S, Utsunomiya A, Inoue Y, Miyagi T, Owatari S, Sawayama Y, Moriuchi Y, Choi I, Shindo T, Yoshida S, Yamasaki S, Yamaguchi T, Fukuda T. Outcome of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Outcome of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Outcome of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica, 103, 5, e211-e214 Haematologica, 103, 5, e211-e214 Haematologica, 103, 5, e211-e214 2018/05 Refereed English Research paper(scientific journal) Disclose to all
Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T, Maekawa T. Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T, Maekawa T. Fujii S, Miura Y, Fujishiro A, Shindo T, Shimazu Y, Hirai H, Tahara H, Takaori-Kondo A, Ichinohe T, Maekawa T. GVHD amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naïve T cell populations. GVHD amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naïve T cell populations. GVHD amelioration by human bone marrow mesenchymal stromal/stem cell-derived extracellular vesicles is associated with peripheral preservation of naïve T cell populations. Stem Cells, 36, 3, 434-445 Stem Cells, 36, 3, 434-445 Stem Cells, 36, 3, 434-445 2018/03 Refereed English Research paper(scientific journal) Disclose to all
Shindo T*, Kitaura K, Ureshino H, Kamachi K, Miyahara M, Doi K, Watanabe T, Sueoka E, Shin-I T, Suzuki R, Kimura S. Shindo T*, Kitaura K, Ureshino H, Kamachi K, Miyahara M, Doi K, Watanabe T, Sueoka E, Shin-I T, Suzuki R, Kimura S. Shindo T*, Kitaura K, Ureshino H, Kamachi K, Miyahara M, Doi K, Watanabe T, Sueoka E, Shin-I T, Suzuki R, Kimura S. Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia. Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia. Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia. Oncoimmunol, 7, 3, e1405204 Oncoimmunol, 7, 3, e1405204 Oncoimmunol, 7, 3, e1405204 2018/03 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S. Ureshino H, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S. Ureshino H, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol, 36, 1, 324-327 Hematol Oncol, 36, 1, 324-327 Hematol Oncol, 36, 1, 324-327 2018/01 Refereed English Research paper(scientific journal) Disclose to all
Kai K, Koga F, Araki N, Shindo T, Eguchi Y, Toda S, Aishima S. Kai K, Koga F, Araki N, Shindo T, Eguchi Y, Toda S, Aishima S. Kai K, Koga F, Araki N, Shindo T, Eguchi Y, Toda S, Aishima S. Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man Autopsy case of systemic EBV-positive T-cell lymphoma of childhood with marked hepatomegaly in a middle-aged man Pathol Int, 67, 8, 431-433 Pathol Int, 67, 8, 431-433 Pathol Int, 67, 8, 431-433 2017/08 Refereed English Research paper(scientific journal) Disclose to all
Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S Itamura H, Kubota Y, Shindo T, Ando T, Kojima K, Kimura S Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg. Clin Lymph Myeloma Leuk, 17, 6, 370-374 Clin Lymph Myeloma Leuk, 17, 6, 370-374 Clin Lymph Myeloma Leuk, 17, 6, 370-374 2017/06 Refereed English Research paper(scientific journal) Disclose to all
進藤 岳郎 進藤 岳郎 成人T細胞白血病(ATL)の診断と治療 成人T細胞白血病(ATL)の診断と治療 ライフライン21, 23 ライフライン21, 23 , 23 2016/10 Japanese Thesis(Others) Disclose to all
Shindo T, Kimura S. 進藤岳郎、木村晋也 Shindo T, Kimura S. Immune defects in multiple myeloma. 多発性骨髄腫における免疫異常 Immune defects in multiple myeloma. Nippon Rinsho, 73, 1, 52-56 日本臨床, 73, 1, 52-56 Nippon Rinsho, 73, 1, 52-56 2015/01 Refereed Japanese Research paper(scientific journal) Disclose to all
進藤 岳郎、木村晋也 進藤 岳郎、木村晋也 慢性骨髄性白血病(CML)治療 〜残された課題〜 慢性骨髄性白血病(CML)治療 〜残された課題〜 血液フロンティア, 23, 2, 73-80 血液フロンティア, 23, 2, 73-80 , 23, 2, 73-80 2013/02 Refereed Japanese Thesis(Others) Disclose to all
Sueoka E, Yamada N, Yamada M, Kubota Y, Urata C, Yoshimura M, Itamura H, Hisatomi T, Fukushima N, Ide M, Yokoo M, Yoshihara M, Kitamura H, Shindo T, Ichinohe T, Higashitani T, Kimura S. 末岡榮三朗、山田尚友、山田麻里江、久保田 寧、浦田千紗子、吉村麻里子、板村英和、久富崇、福島伯泰、出勝、横尾眞子、吉原麻里、蒲池和晴、北村浩晃、進藤岳郎、一戸辰夫、東谷孝徳、木村晋也 Sueoka E, Yamada N, Yamada M, Kubota Y, Urata C, Yoshimura M, Itamura H, Hisatomi T, Fukushima N, Ide M, Yokoo M, Yoshihara M, Kitamura H, Shindo T, Ichinohe T, Higashitani T, Kimura S. Management of transfusional iron overload. 輸血後鉄過剰症の現状と問題点 Management of transfusional iron overload. Japanese J of Transfusion and Cell Therapy, 59, 1, 73-78 日本輸血細胞治療学会誌, 59, 1, 73-78 Japanese J of Transfusion and Cell Therapy, 59, 1, 73-78 2013/01 Refereed Japanese Research paper(scientific journal) Disclose to all
Shindo T, Yumoto Y, Yoshida M, Okuda T 進藤岳郎、湯本義一、吉田道明、奥田哲也 Shindo T, Yumoto Y, Yoshida M, Okuda T Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy. VAD療法およびMP療法が奏効した非分泌型形質細胞白血病 Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy. Rinsho Ketsueki, 43, 2, 107-111 臨床血液, 43, 2, 107-111 Rinsho Ketsueki, 43, 2, 107-111 2002/02 Refereed Japanese Research paper(scientific journal) Disclose to all
Akutagawa T, Shindo T*, Yamanouchi K, Hayakawa M, Ureshino H, Tsuruoka N, Sakata Y, Shimoda R, Noguchi R, Furukawa K, Morita S, Iwakiri R, Kimura S, Matsumoto M, Fujimoto K Akutagawa T, Shindo T*, Yamanouchi K, Hayakawa M, Ureshino H, Tsuruoka N, Sakata Y, Shimoda R, Noguchi R, Furukawa K, Morita S, Iwakiri R, Kimura S, Matsumoto M, Fujimoto K Persistent Gastrointestinal Angiodysplasia in Heyde’s syndrome after aortic valve replacement. Persistent Gastrointestinal Angiodysplasia in Heyde’s syndrome after aortic valve replacement. Intern Med, 56, 18, 2431-2433 , 56, 18, 2431-2433 Intern Med, 56, 18, 2431-2433 2017/09 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota Y, Ando T, Kojima K, Kimura S. Ureshino H, Kizuka H, Kusaba K, Sano H, Nishioka A, Shindo T, Kubota Y, Ando T, Kojima K, Kimura S. 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). 5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10). Int J Hematol, 105, 5, 692-696 , 105, 5, 692-696 Int J Hematol, 105, 5, 692-696 2017/05 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Shindo T, Tanaka H, Kimura S. Ureshino H, Shindo T, Tanaka H, Kimura S. Chronic myelogenous leukemia and NK cell immunity. Chronic myelogenous leukemia and NK cell immunity. Rinsho Ketsueki, 58, 4, 381-388 , 58, 4, 381-388 Rinsho Ketsueki, 58, 4, 381-388 2017/04 Refereed Japanese Research paper(scientific journal) Disclose to all
Ureshino H, Nishioka A, Kojima K, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Ureshino H, Nishioka A, Kojima K, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Subdural hematoma associated with dasatinib and intrathecal methotrexate treatment in Philadelphia chromosome-positive acute lymphoblastic leukemia. Subdural hematoma associated with dasatinib and intrathecal methotrexate treatment in Philadelphia chromosome-positive acute lymphoblastic leukemia. Intern Med, 55, 18, 2703-2706 , 55, 18, 2703-2706 Intern Med, 55, 18, 2703-2706 2016/09 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Shindo T*, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, Kimura H, Samukawa M, Kusunoki S, Miyahara M, Shin-I T, Suzuki R, Sakaguchi S, Kimura S. Ureshino H, Shindo T*, Nishikawa H, Watanabe N, Watanabe E, Satoh N, Kitaura K, Kitamura H, Doi K, Nagase K, Kimura H, Samukawa M, Kusunoki S, Miyahara M, Shin-I T, Suzuki R, Sakaguchi S, Kimura S. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T cell leukemia. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T cell leukemia. Cancer Immunol Res, 4, 8, 644-649 , 4, 8, 644-649 Cancer Immunol Res, 4, 8, 644-649 2016/08 Refereed English Research paper(scientific journal) Disclose to all
Ureshino H, Nishioka A, Kojima K, Suzuki M, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Ureshino H, Nishioka A, Kojima K, Suzuki M, Kizuka H, Sano H, Shindo T, Kubota Y, Ando T, Kimura S. Rituximab-induced acute thrombocytopenia in high tumor burden follicular lymphoma. Rituximab-induced acute thrombocytopenia in high tumor burden follicular lymphoma. Intern Med, 55, 15, 2061-2064 , 55, 15, 2061-2064 Intern Med, 55, 15, 2061-2064 2016/08 Refereed English Research paper(scientific journal) Disclose to all
Itamura H, Shindo T*, Tawara I, Kubota Y, Kariya R, Okada S, Komanduri KV, Kimura S Itamura H, Shindo T*, Tawara I, Kubota Y, Kariya R, Okada S, Komanduri KV, Kimura S The MEK inhibitor trametinib separates murine Graft-versus-Host Disease from Graft-versus-Tumor Effects. The MEK inhibitor trametinib separates murine Graft-versus-Host Disease from Graft-versus-Tumor Effects. JCI Insight, 1, 10, e86331 , 1, 10, e86331 JCI Insight, 1, 10, e86331 2016/07 Refereed English Research paper(scientific journal) Disclose to all
Kitamura H, Shindo T*, Yakushiji Y, Yoshihara M, Eriguchi M, Kubota Y, Noguchi T, Kimura S. Kitamura H, Shindo T*, Yakushiji Y, Yoshihara M, Eriguchi M, Kubota Y, Noguchi T, Kimura S. Domino-style cerebral bleeding in a patient with immune thrombocytopenic purpura. Domino-style cerebral bleeding in a patient with immune thrombocytopenic purpura. JAMA Neurol, 73, 4, 474-475 , 73, 4, 474-475 JAMA Neurol, 73, 4, 474-475 2016/04 Refereed English Research paper(scientific journal) Disclose to all
Fuji S, Shindo T Fuji S, Shindo T Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation in adult T-cell leukemia. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation in adult T-cell leukemia. Stem Cell Investig, 3, 70 , 3, 70 Stem Cell Investig, 3, 70 2016/03 Refereed English Research paper(scientific journal) Disclose to all
Kamachi K, Fukushima N, Ando T, Sato K, Ohshima K, Yokoo M, Shindo T, Kubota Y, Kojima K, Kimura S. Kamachi K, Fukushima N, Ando T, Sato K, Ohshima K, Yokoo M, Shindo T, Kubota Y, Kojima K, Kimura S. Coexistence of ALK- anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia. Coexistence of ALK- anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia. Ann Hematol, 94, 3, 539-540 , 94, 3, 539-540 Ann Hematol, 94, 3, 539-540 2015/03 Refereed English Research paper(scientific journal) Disclose to all
Fuji S, Shindo T Fuji S, Shindo T T-cell characterization using multicolor flow cytometry after allogeneic hematopoietic stem-cell transplantation. T-cell characterization using multicolor flow cytometry after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol, 32, 17, 1859-1860 , 32, 17, 1859-1860 J Clin Oncol, 32, 17, 1859-1860 2014/09 Refereed English Research paper(scientific journal) Disclose to all
Yoshihara M, Itamura H, Fukushima N, Itoh M, Furukawa D, Nagatomo D, Kamachi K, Kitamura H, Shindo T, Kubota Y, Sueoka E, Morita S, Ichinohe T, Kimura S. Yoshihara M, Itamura H, Fukushima N, Itoh M, Furukawa D, Nagatomo D, Kamachi K, Kitamura H, Shindo T, Kubota Y, Sueoka E, Morita S, Ichinohe T, Kimura S. Therapeutic management in cardiac lymphoma. Therapeutic management in cardiac lymphoma. Leuk Lymphoma, 55, 5, 1215-1217 , 55, 5, 1215-1217 Leuk Lymphoma, 55, 5, 1215-1217 2014/05 Refereed English Research paper(scientific journal) Disclose to all
Shindo T, Kim TK, Benjamin CL, Wieder ED, Levy RB, Komanduri KV. Shindo T, Kim TK, Benjamin CL, Wieder ED, Levy RB, Komanduri KV. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood, 121, 23, 4617-4626 , 121, 23, 4617-4626 Blood, 121, 23, 4617-4626 2013/06 Refereed English Research paper(scientific journal) Disclose to all
Shindo T, Ishikawa T, Fukunaga A, Hori T, and Uchiyama T. Shindo T, Ishikawa T, Fukunaga A, Hori T, and Uchiyama T. Growth and differentiation advantages of CD4+OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. Growth and differentiation advantages of CD4+OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Tranplant, 14, 3, 268-281 , 14, 3, 268-281 Biol Blood Marrow Tranplant, 14, 3, 268-281 2008/03 Refereed English Research paper(scientific journal) Disclose to all
Fukunaga A, Ishikawa T, Kishihata M, Shindo T, Hori T, and Uchiyama T. Fukunaga A, Ishikawa T, Kishihata M, Shindo T, Hori T, and Uchiyama T. Altered homeostasis of CD4+ memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool. Altered homeostasis of CD4+ memory T cells in allogeneic hematopoietic stem cell transplant recipients: chronic graft-versus-host disease enhances T cell differentiation and exhausts central memory T cell pool. Biol Blood Marrow Transplant, 13, 10, 1176-1184 , 13, 10, 1176-1184 Biol Blood Marrow Transplant, 13, 10, 1176-1184 2007/10 Refereed English Research paper(scientific journal) Disclose to all

  • <<
  • >>
Title language:
Conference Activities & Talks
Title Title(Japanese) Title(English) Conference Conference(Japanese) Conference(English) Promotor Promotor(Japanese) Promotor(English) Date Language Assortment Disclose
Killer immunoglobulin-like receptor (KIR)で読み解く臨床免疫学[Invited] Killer immunoglobulin-like receptor (KIR)で読み解く臨床免疫学 [Invited] 第17回日本組織適合性学会近畿地方会 第17回日本組織適合性学会近畿地方会 2019/03/02 Japanese Symposium workshop panel(nominated) Disclose to all
慢性骨髄性白血病におけるチロシンキナーゼ阻害剤の効果はKIRおよびHLAのアリル多型と相関する[Invited] 慢性骨髄性白血病におけるチロシンキナーゼ阻害剤の効果はKIRおよびHLAのアリル多型と相関する [Invited] 第46回日本臨床免疫学会総会 第46回日本臨床免疫学会総会 2018/11/08 Japanese Symposium workshop panel(nominated) Disclose to all
Phosphorylation of ERK1/2 in CD4+ T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation CD4 T細胞におけるERK1/2のリン酸化は同種造血幹細胞移植後の急性GVHDと相関する Phosphorylation of ERK1/2 in CD4+ T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation The 80th annual meeting of the Japanese Society of Hematology 第80回日本血液学会学術集会 The 80th annual meeting of the Japanese Society of Hematology 2018/10/12 English Oral presentation(general) Disclose to all
慢性骨髄性白血病におけるKIRとHLAのアリル多型はチロシンキナー ゼ阻害剤の治療効果と相関する 慢性骨髄性白血病におけるKIRとHLAのアリル多型はチロシンキナー ゼ阻害剤の治療効果と相関する 第26回日本組織適合性学会大会 第26回日本組織適合性学会大会 2017/10 Japanese Symposium workshop panel(nominated) Disclose to all
MEK阻害剤トラメチニブはラット肺移植後の胸腺機能を温存しつつ遅発性拒絶を抑制する MEK阻害剤トラメチニブはラット肺移植後の胸腺機能を温存しつつ遅発性拒絶を抑制する 第27回日本組織適合性学会大会 第27回日本組織適合性学会大会 2017/09/21 Japanese Oral presentation(general) Disclose to all
TCR Repertoire, Effector Regulatory T-cells and KIR Genotyping Uncover Immunological Dynamics in Mogamulizumab-treated ATL TCR Repertoire, Effector Regulatory T-cells and KIR Genotyping Uncover Immunological Dynamics in Mogamulizumab-treated ATL International Conference of Human Retrovirology HTLV and related viruses International Conference of Human Retrovirology HTLV and related viruses 2017 English Oral presentation(general) Disclose to all
The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT and antiviral immunity.[Invited] The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT and antiviral immunity. [Invited] The 7th Japanese Society of Hematology (JSH) International Symposium The 7th Japanese Society of Hematology (JSH) International Symposium 2016/05/14 English Oral presentation(keynote) Disclose to all
The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT effects. The MEK inhibitor trametinib selectively suppresses GVHD, while sparing GVT effects. Biol Blood Marrow Transplant Biol Blood Marrow Transplant 2015/02 English Oral presentation(general) Disclose to all
Trametinib selectively inhibits alloreactivity while sparing virus-specific T cells. Trametinib selectively inhibits alloreactivity while sparing virus-specific T cells. Biol Blood Marrow Transplant Biol Blood Marrow Transplant 2014/02 English Oral presentation(general) Disclose to all
Title language:
Awards
Title(Japanese) Title(English) Organization name(Japanese) Organization name(English) Date
Best Post-doctoral fellow University of Miami Sylvester Poster Session 2011/08/01
Abstract Achievement Award American Society of Hematology (ASH) The 53rd Annual Meeting of the American Society of Hematology (ASH) 2011/12/01
麒麟児賞 Kirinji Award 第9回血液学若手研究者勉強会 The 9th Meeting of young investigators in hematology (KIRIN-JUKU) 2013/07/01
一般研究助成 Grant-in-aid for Medical Research 日本白血病研究基金 Japan Leukemia Research Fund (JLRF) 2013/11/08
一般研究助成 Grant-in-aid for Medical Research 先進医薬研究振興財団 SENSHIN Medical Research Foundation 2013/12/01
一般研究助成 Grant-in-aid for Medical Research 武田科学振興財団 Takeda Science Foundation 2016/11/19
一般研究助成 Grant-in-aid for Medical Research 先進医薬研究振興財団 SENSHIN Medical Research Foundation 2016/12/01
一般研究助成 Grant-in-aid for Medical Research 小林がん学術振興財団 Kobayashi Cancer Research Foundation 2017/06/17
学術奨励賞(優秀賞) Encouragement Award 第26回日本組織適合性学会大会 The 26th annual meeting of the Japanese Society of Histocompatibility and Immunogenetics 2017/10/28
京都大学医学部附属病院病院長賞 京都大学医学部附属病院 2019/03/31
External funds: competitive funds and Grants-in-Aid for Scientific Research (Kakenhi)
Type Position Title(Japanese) Title(English) Period
科研費:基盤研究C Representative MEK阻害剤を用いた移植後GVHDの選択的抑制と感染・腫瘍免疫の温存 2013/04/01-2017/03/31
AMED橋渡し研究シーズプログラム・シーズA Assignment MEK阻害剤トラメチニブを用いた肺移植後慢性拒絶の抑制 2017/04/01-2018/03/31
AMED橋渡し研究シーズプログラム・シーズA Representative コビメチニブを用いた造血幹細胞移植後の免疫再構築促進 2018/04/01-2019/03/31
科研費・基盤研究B Assignment 肺移植後の慢性拒絶撲滅を目指す、自然免疫を温存した選択的免疫抑制療法の創出 2018/04/01-2021/03/31
科研費・基盤研究C Representative KIRアリル多型に着目した造血幹細胞移植における免疫の最適化 2019/04/01-2022/03/31
External funds: other than those above
System Main person Title(Japanese) Title(English) Period
日本白血病研究基金 進藤岳郎 MEK阻害剤を用いたGVHDの選択的抑制と抗腫瘍免疫の温存 2013/12/01-2014/11/30
先進医薬研究振興財団 進藤岳郎 MEK阻害剤を用いたGVHDの選択的抑制と抗腫瘍免疫の温存 2013/12/01-
武田科学振興財団 進藤岳郎 MEK阻害剤を用いた造血幹細胞移植後免疫抑制の最適化 2016/11/19-
先進医薬研究振興財団 進藤岳郎 MEK阻害剤を用いた造血幹細胞移植後免疫抑制の最適化 2016/12/01-
一般研究助成 進藤岳郎 MEK阻害剤を用いた造血幹細胞移植後免疫抑制の最適化 2017/06/17-
ノバルティス研究助成金 進藤岳郎 KIRアリル多型に着目した造血幹細胞移植の最適化 2018/10/01-
上原記念生命科学財団・研究助成金 進藤岳郎 同種造血幹細胞移植におけるKIRアレルの機能解析 2019/03/01-2020/02/28
Awards received by supervised students
Student name Award title Giver Date
板村英和 ベストポスター賞 がん分子標的治療学会 2015/07/
板村英和 一般研究助成 かなえ財団 2016/03/01
嬉野博志 優秀論文賞 佐賀大学 2017/03/24
板村英和 海外留学助成 上原記念財団 2017/04/01
嬉野博志 佐賀大学医学部長賞 佐賀大学 2019/03/01
嬉野博志 佐賀大学内科同門会賞 佐賀大学 2019/03/01
Other activities (private companies, NPOs, etc.)
Company name Activity Period
Cancer Net Japan AKIBA Cancer Forumでの啓発講演 2015/08/05-2015/08/05
つばさフォーラム京都 血液疾患に関する啓発講演 2017/07/29-2017/07/29
つばさフォーラム京都 血液疾患に関する啓発講演 2018/08/25-2018/08/25
関西HTLV-1ねっと 講演 2019/03/17-2019/03/17